Current Review of Systemic Juvenile Idiopathic Arthritis: What Do Paediatricians Need to Know?  

作　　者：Asma R. Albaker Asma R. Albaker(Paediatrics Department, College of Medicine, King Saud Medical City;and King Saud University, Riyadh, Saudi Arabia)

机构地区：[1]Paediatrics Department, College of Medicine, King Saud Medical City and King Saud University, Riyadh, Saudi Arabia

出　　处：《Open Journal of Pediatrics》2020年第4期769-801,共33页儿科学期刊（英文）

摘　　要：Systemic </span><span><span style="font-family:Verdana;">juvenile idiopathic arthritis is classified as an autoimmune entity and a subtype of juvenile idiopathic arthritis, although it has many features of autoinflammatory-type of diseases. This review article will elaborate on the disease’s pathogenesis and its proposed relation to autoinflammatory diseases including defective innate immunity and phagocytosis response leading </span><span style="font-family:Verdana;">excessive</span><span style="font-family:Verdana;"> cytokine release. It also explains the disease’s epidemiology, clinical phenotype, diagnostic challenges, complications </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> current advancements in the treatment of systemic juvenile idiopathic arthritis, such as IL-1 and IL-6 antagonists </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> their impact on the disease trajectory. Care of patients with systemic juvenile idiopathic arthritis requires a comprehensive multidisciplinary team to optimize the care and avoid complications of the disease itself such as growth impairment, macrophage activation syndrome </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the complications of immunosuppressant and immun</span></span><span style="font-family:Verdana;">omodulatory treatments.Systemic </span><span><span style="font-family:Verdana;">juvenile idiopathic arthritis is classified as an autoimmune entity and a subtype of juvenile idiopathic arthritis, although it has many features of autoinflammatory-type of diseases. This review article will elaborate on the disease’s pathogenesis and its proposed relation to autoinflammatory diseases including defective innate immunity and phagocytosis response leading </span><span style="font-family:Verdana;">excessive</span><span style="font-family:Verdana;"> cytokine release. It also explains the disease’s epidemiology, clinical phenotype, diagnostic challenges, complications </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> current advancements in the treatment of systemic juvenile idiopathic arthritis, such as IL-1 and IL-6 antagonists </span><span style="font-family:Verdana;">and</span><span style="font-family:Verdana;"> their impact on the disease trajectory. Care of patients with systemic juvenile idiopathic arthritis requires a comprehensive multidisciplinary team to optimize the care and avoid complications of the disease itself such as growth impairment, macrophage activation syndrome </span><span style="font-family:Verdana;">or</span><span style="font-family:Verdana;"> the complications of immunosuppressant and immun</span></span><span style="font-family:Verdana;">omodulatory treatments.

关 键 词：Juvenile Idiopathic Arthritis Systemic Juvenile Idiopathic Arthritis AUTOINFLAMMATORY ARTHRITIS BIOLOGICS 

分 类 号：R59[医药卫生—内科学]